[HTML][HTML] ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)
Abstract Abstract 207 Background: Results from the phase 3, international, randomized
ENESTnd trial have demonstrated the superior efficacy of nilotinib over imatinib with …
ENESTnd trial have demonstrated the superior efficacy of nilotinib over imatinib with …
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.
RA Larson, PD Le Coutre, J Reiffers… - Journal of Clinical …, 2010 - ascopubs.org
6501 Background: Study results of ENESTnd at 12 month (mo) demonstrated superior
efficacy of nilotinib 300 and 400 mg bid over imatinib. Methods: 846 CML-CP pts were …
efficacy of nilotinib 300 and 400 mg bid over imatinib. Methods: 846 CML-CP pts were …
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.
RA Larson, D Kim, G Rosti, L Stenke… - Journal of Clinical …, 2011 - ascopubs.org
6511 Background: Nilotinib demonstrated superiority vs imatinib in ENESTnd at 12 months
(mo). Here, we present data with a minimum follow-up (f/u) of 24 mo. Methods: 846 CML-CP …
(mo). Here, we present data with a minimum follow-up (f/u) of 24 mo. Methods: 846 CML-CP …
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
[HTML][HTML] Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis
Introduction: In Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed
Patients (ENESTnd), patients with CML-CP achieved deeper molecular responses and …
Patients (ENESTnd), patients with CML-CP achieved deeper molecular responses and …
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).
H Kantarjian, IW Flinn, S Goldberg, U Bunworasate… - 2012 - ascopubs.org
6509^ Background: In ENESTnd, nilotinib significantly reduced progression to AP/BC and
demonstrated superior rates of MMR, MR4, and MR4. 5 vs imatinib with f/u of 2 yrs. Methods …
demonstrated superior rates of MMR, MR4, and MR4. 5 vs imatinib with f/u of 2 yrs. Methods …
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
HM Kantarjian, TP Hughes, RA Larson, DW Kim… - Leukemia, 2021 - nature.com
In the ENESTnd study, with≥ 10 years follow-up in patients with newly diagnosed chronic
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …
myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative …
[HTML][HTML] Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term …
RA Larson, DW Kim, S Issaragrilsil, P le Coutre… - Blood, 2014 - Elsevier
Abstract Introduction In Evaluating NIL Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd), frontline NIL has consistently demonstrated good …
Diagnosed Patients (ENESTnd), frontline NIL has consistently demonstrated good …
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
Abstract Treatment with a tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is currently the
standard of care for patients with chronic myeloid leukemia (CML) in chronic phase (CML …
standard of care for patients with chronic myeloid leukemia (CML) in chronic phase (CML …
Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the …
G Saglio, DW Kim, S Issaragrisil, PD le Coutre… - 2009 - ashpublications.org
Abstract Abstract LBA-1 Background: Nilotinib is a highly potent and the most selective
inhibitor of BCR-ABL, the only proven molecular target for CML therapy. ENESTnd …
inhibitor of BCR-ABL, the only proven molecular target for CML therapy. ENESTnd …